Canada tackles cardiovascular device relicensing
This article was originally published in Clinica
Executive Summary
Canada's Therapeutic Products Directorate (TPD) - until this month the Therapeutic Products Programme - is to set up a cardiovascular products working group to look at the issue of licence reviews. The group will seek to determine in which cases clinical data will be required to support amendment applications. To this effect it will aim to define "significant change".